Eliksa Therapeutics

Eliksa Therapeutics is a small, venture-backed biotechnology company based in Philadelphia, Pennsylvania. With a team of three employees, Eliksa focuses on developing innovative therapies for unmet medical needs in the ocular and cardiovascular fields. The company's primary product, ELK-003, is a novel biological designed to modulate inflammation, cell recovery, and tissue healing. ELK-003 targets multiple pathways, offering a unique approach to treating various ocular and cardiovascular conditions. Eliksa Therapeutics stands out due to its proprietary cGMP production facility, ensuring high-quality and consistent manufacturing of its therapeutic candidates. The company also boasts a robust clinical pipeline, demonstrating its commitment to advancing promising treatments through rigorous clinical trials. For more information about Eliksa Therapeutics and its innovative therapies, visit their website at eliksa.com.